about
Targeted Therapy in Biliary Tract CancersMolecular profiling of biliary tract cancer: a target rich diseaseHER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologistsTargeted therapy in biliary tract cancers-current limitations and potentials in the future.The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Therapeutic implication of HER2 in advanced biliary tract cancer.Pertuzumab in gastrointestinal cancer.Novel investigational therapies for treating biliary tract carcinoma.Current Progress in Immunotherapy for the Treatment of Biliary Cancers.HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications.Biliary cancer: Utility of next-generation sequencing for clinical management.Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes.Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients.Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers.Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.New molecular and immunotherapeutic approaches in biliary cancer.Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico.Emerging role of precision medicine in biliary tract cancers
P2860
Q26798443-4EC9CBBA-7FF5-47F2-973B-D2F9FF8EE0AFQ28072275-EC20F454-E26B-44C3-990A-1C782FF970E5Q28078111-6F320014-4CEC-42C5-A328-35B554035F70Q30234532-69A0A940-9642-4AA9-94DB-16779F24F488Q33656860-B7B4BDB4-2598-453D-98DA-DAEE92046A56Q34553167-2745324A-2E3A-4D19-96A9-FA3354D300A6Q37017110-ED408587-19C9-4B7F-9060-C5B31D1A2CBBQ37628969-B76970C8-2D15-432D-89A4-BD6E9D2B39E0Q38653309-6441C57C-F031-49B6-AD7A-9B6678A63EBCQ38799963-0B738D31-EEC4-45C8-94DD-B229DA08CDB6Q38830071-FC8CAC2A-0B85-49BB-B659-03B567F2EDBBQ39040859-1B13ACC5-70F0-4B53-A387-5DA66BA50F94Q39289707-A1A6DE94-8376-4A1C-9C4F-291C2C4E6DC2Q39396785-08D89731-3AEC-4F7D-9EE6-96D7E5FC6382Q40327923-63BCA88A-3EAE-4524-AD75-10B4D39EEB29Q40421102-B76F735A-A579-4C54-8C43-077EE7EDE109Q41431886-7F4ED4B5-FE51-4193-8DA2-B03F89F485CAQ47103332-A6A59455-AEB1-4507-9DEB-DC404BDA21A1Q50127508-40CD1DDC-AF29-47D0-9096-6A6ABC532A8EQ52668202-801B9918-B3C7-4D8B-B31F-4828FE0C83E3Q54476966-893A4C94-9254-4EC1-AAE0-EB75E8627308Q55481891-6B49361A-D41B-4E42-AD8B-1BAD8CD4C923Q57298169-D7335936-FA6C-4664-8BD6-E18387FB278C
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
HER2/neu-directed therapy for biliary tract cancer.
@ast
HER2/neu-directed therapy for biliary tract cancer.
@en
type
label
HER2/neu-directed therapy for biliary tract cancer.
@ast
HER2/neu-directed therapy for biliary tract cancer.
@en
prefLabel
HER2/neu-directed therapy for biliary tract cancer.
@ast
HER2/neu-directed therapy for biliary tract cancer.
@en
P2093
P2860
P1476
HER2/neu-directed therapy for biliary tract cancer.
@en
P2093
Abby B Siegel
Ahmed O Kaseb
Chaitanya Churi
Christian Barrera
Humaid Alshamsi
Lopa Mishra
Melanie B Thomas
Milind Javle
Mingxin Zuo
Rachna Shroff
P2860
P2888
P356
10.1186/S13045-015-0155-Z
P577
2015-05-29T00:00:00Z
P5875
P6179
1041103687